Abstracts Archive - Page 2 of 1683 - ATC Abstracts

2022 American Transplant Congress
Single Blind Randomized Controlled Trial Comparing BNT162b2 Vs JNJ-78436735 Vaccine As An Additional Dose After Two Doses Of BNT162b2 Vaccine In Solid Organ Transplant (SOT) Recipients
Y. Natori¹, E. Martin², A. Mattiazzi³, J. Bini Viotti¹, K. S. Ortecho⁴, S. Pallikkuth⁵, S. Anjan¹, J. Simkins¹, G. Guerra³
¹Department of Medicine, Division of Infectious Diseases, University of Miami, Miami, FL, ²Department of Medicine, Division of Hepatology, University of Miami, Miami, FL, ³Department of Medicine, Division of Nephrology, University of Miami, Miami, FL, ⁴Miami Transplant Institute, Jackson Health System, Miami, FL, ⁵University of Miami, Miami, FL
*Purpose: Even though a high efficacy and immunogenicity of COVID-19 vaccines have been reported in the general population, vaccine immunogenicity is suboptimal in SOT recipients…
2022 American Transplant Congress
CD8⁺ T Cells Differentiate into a CD43-expressing Effector Population After Transplantation
G. Cohen, M. A. Kallarakal, S. M. Krummey
Department of Pathology, Johns Hopkins University, Baltimore, MD
*Purpose: Despite a significantly reduced toxicity profile and improved long-term graft function versus calcineurin inhibitors, widespread adaptation of belatacept (CTLA-4 Ig) has been limited due…
2022 American Transplant Congress
Pegylated Lacritin N-104 Promotes Mouse Islet Stabilization and Prevents Diabetes Progression in the Non-Obese Diabetic (NOD) Mouse Model
M. Ma¹, P. Chhabra¹, G. Laurie², K. L. Brayman¹
¹Department of Surgery, University of Virginia Health System, Charlottesville, VA, ²Department of Cell Biology, University of Virginia Health System, Charlottesville, VA
*Purpose: To investigate if PEGylated Lacritin N-104 (PEG N-104) prevents the progression of type 1 diabetes (T1D) in the NOD mouse.*Background: Lacritin is a multifunctional…
2022 American Transplant Congress
Results Of The Ctot19 Trial: Infliximab (IFX) Induction Does Not Impact 2-year Outcomes In Deceased Donor Kidney Transplant Recipients
P. Heeger¹, B. Armstrong², T. Alhamad³, D. Brennan⁴, J. Bromberg⁵, S. Bunnapradist⁶, S. Chandran⁷, R. Fairchild⁸, D. Foley⁹, R. Formica¹⁰, I. W. Gibson¹¹, D. Hricik¹², K. Kesler², R. B. Mannon¹³, M. Menon¹⁰, K. Newell¹⁴, P. Nickerson¹¹, J. Odim¹⁵, E. Poggio⁸, R. Sung¹⁶, R. Shapiro¹, K. Tinckam¹⁷, F. Vincenti⁷
¹Mount Sinai, New York, NY, ²Rho, Durham, NC, ³Washington U, Saint Louis, MO, ⁴Johns Hopkins, Baltimore, MD, ⁵U Maryland, Baltimore, MD, ⁶UCLA, Los Angeles, CA, ⁷UCSF, San Francisco, CA, ⁸Cleveland Clinic, Cleveland, OH, ⁹U Wisconsin, Madison, WI, ¹⁰Yale, New Haven, CT, ¹¹U Manitoba, Winnipeg, MB, Canada, ¹²U Hosp Case, Cleveland, OH, ¹³U Nebraska, Omaha, NE, ¹⁴Emory, Atlanta, GA, ¹⁵NIAID NIH, Rockville, MD, ¹⁶U Michigan, Ann Arbor, MI, ¹⁷U Hlth Network, Toronto, ON, Canada
*Purpose: Ischemia-reperfusion (IR) of a kidney transplant (KTx) up-regulates tumor necrosis factor alpha (TNF) production within the allograft. IR-induced TNF amplifies post-KTx allograft inflammation and…
2022 American Transplant Congress
A Randomized Phase 2 Study Of Mau868 Vs Placebo To Treat Bk Viremia In Kidney Transplant Recipients
S. Jordan¹, A. P. Limaye², B. Fischbach³, P. Sood⁴, S. Collette⁵, L. Gasink⁶, M. W. Fordyce⁷, C. J. Lin⁷, M. Hodges⁶, D. C. Brennan⁸
¹Cedars-Sinai Medical Center, Los Angeles, CA, ²University of Washington, Seattle, WA, ³Dallas Nephrology Associates, Inc, Dallas, TX, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada, ⁶previous employee/consultant for Amplyx Pharmaceuticals, San Diego, CA, ⁷Vera Therapeutics, Inc, Brisbane, CA, ⁸Johns Hopkins School of Medicine, Baltimore, MD
*Purpose: To assess the safety and efficacy of MAU868, a BK virus-specific monoclonal antibody, in adult kidney transplant recipients with BK viremia.*Methods: This is a…
2022 American Transplant Congress
Long-Term Outcomes of Liver Transplantation (LT) Using Grafts from Donors with Active and Chronic Hepatitis B Virus (HBV) Infection; Multi-Center Cohort Study
S. Suh¹, S. Gang², Y. Choi², S. Hong², N. Yi², K. Lee², K. Suh²
¹Chung-Ang University, Seoul, Korea, Republic of, ²Seoul National University, Seoul, Korea, Republic of
*Purpose: Liver grafts from donors with hepatitis B infection contributed to expand the donor pool under the Hepatitis B immunoglobulin (HBIG) and antiviral agents (NA:…
2022 American Transplant Congress
Functional Recellularized Patient Derived Endothelium; A Human Vascular Graft Approach
H. Tejeda Mora¹, J. Willemse², Y. den Hartog¹, I. Schurink², M. M. Verstegen², J. de Jonge², R. C. Minnee², M. W. van den Hoogen², C. C. Baan¹, L. J. van der Laan², M. J. Hoogduijn¹
¹Transplant Institute - Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands, ²Transplant Institute - Department of Surgery, Erasmus Medical Center, Rotterdam, Netherlands
*Purpose: In transplantation, the endothelial lining is the first barrier between the donor organ and recipient immune system. Damaged endothelium exposes extracellular matrix (ECM) molecules…
2022 American Transplant Congress
Long-Term Kidney Allotransplant Acceptance is Defined by a Shift from a T Cell to a B Cell Rich Immune Microenvironment Within the Graft
E. S. Szuter¹, T. Yokose¹, M. T. Guinn¹, J. Ge², I. Rosales³, B. Kwon⁴, P. S. Russell¹, A. Cuenca², D. Kreisel⁵, P. Sage⁶, J. C. Madsen¹, R. B. Colvin³, A. Alessandrini¹
¹Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, ²Department of Surgery, Boston Children's Hospital, Boston, MA, ³Department of Pathology, Massachusetts General Hospital, Boston, MA, ⁴Harvard College, Cambridge, MA, ⁵Department of Surgery, Washington University, St. Louis, MO, ⁶Transplantation Research Center, Renal Division, Brigham and Women’s Hospital, Boston, MA
*Purpose: Mouse kidney allografts are spontaneously accepted in select, fully-mismatched donor-recipient strain combinations, such as DBA/2J to C57BL/6 (B6). Tolerant renal grafts develop aggregates of…
2022 American Transplant Congress
Tacrolimus After Rabbit Antithymocyte Globulin And Infliximab Induction Immunosuppression In Kidney Transplantation
O. Viklicky¹, G. Bold², O. Bestard³, P. Hruba¹, I. Zahradka¹, N. M. Otto², M. Stein², A. Sefrin², S. Christakoudi⁴, P. M. Reinke²
¹Institute for Clinical and Experimental Medicine, Prague, Czech Republic, ²Charité, Berlin, Germany, ³Vall d'Hebron, Barcelona, Spain, ⁴King's College, London, United Kingdom
*Purpose: Selective targeting of effector/memory T cells as induction immunosuppression has been discussed in kidney transplantation. Confidence-interval-estimation study may help to estimate range of the…
2022 American Transplant Congress
Impact of Cold Ischemia Times on 1 Year Kidney Transplant Outcomes
T. Fletchinger, L. Burdine
Department of Surgery, University of Arkansas for Medical Sciences, Little Rock, AR
*Purpose: Recent organ allocation changes have increased travel and subsequent cold ischemia times (CIT) of kidney allografts. We sought to investigate the impact of prolonged…